References
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–1104.
- Gomez-Reino JJ, Carmona L, Valverde VR, et al.; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122–2127.
- Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766–1772.
- Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.
- Diel R, Hauer B, Loddenkemper R, et al. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 2009;63:329–334.
- Fonseca JE, Canhao H, Silva C, et al. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port 2006;31:247–253. (Article in Portuguese)
- Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620–132.
- Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185–1206.
- Korean Guideline for Tuberculosis. Joint Committee for the revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korea Centers for Disease Control and Prevention: Osong, KoreaAvailable online at: http://www.lungkorea.org/image/mail/file_110217.pdf. Assessed December 2014. (In Korean).
- Jung YJ, Lyu J, Yoo B, et al. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment. Int J Tuberc Lung Dis 2012;16:1300–1306.
- Jung YJ, Lee JY, Jo KW, et al. The ‘either test positive’ strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 2014;18:428–434.
- Jo KW, Hong Y, Jung YJ, et al. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. Respir Med 2013;107:1797–1802.
- Park S, Jo KW, Yoo B, et al. Comparison of LTBI treatment regimens for patients receiving anti-tumor necrosis factor treatment. Int J Tuberc Lung Dis 2015;19:342–348.
- Kim HC, Jo KW, Jung YJ, et al. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and Quantiferon-TB Gold InTube assay. Scand J Infect Dis 2014;46:763–769.
- Menzies D, Dion MJ, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445–449.
- British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800–805.
- Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha–California, 2002–2003. MMWR Morb Mortal Wkly Rep 2004;53:683–686.
- Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295–299.
- Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884–1894.